COVID Variant Tracking
CorvGenSurv (Coronavirus Genomic Surveillance)
We invented a novel COVID whole genome sequencing technology at the onset of pandemic to overcome genome coverage dropouts of the de-facto standard of short-read sequencing methods. CorvGenSurv has streamlined complex whole genome sequencing processes and downstream bioinformatics into one standardized workflow. We rapidly sequence confirmed positive cases for efficient variant tracking. CorvGenSurv is expected to allow prompt and targeted interventions on breakthrough cases after vaccination [youtube link: https://www.youtube.com/watch?v=ZBoVeP_R5Gw ].
We invented a novel COVID whole genome sequencing technology at the onset of pandemic to overcome genome coverage dropouts of the de-facto standard of short-read sequencing methods. CorvGenSurv has streamlined complex whole genome sequencing processes and downstream bioinformatics into one standardized workflow. We rapidly sequence confirmed positive cases for efficient variant tracking. CorvGenSurv is expected to allow prompt and targeted interventions on breakthrough cases after vaccination [youtube link: https://www.youtube.com/watch?v=ZBoVeP_R5Gw ].
HIV Genomic Surveillance
HIDA (HIV Incidence and Drug Resistance Assay)
We invented microdrop HIV sequencing for accurate and high-throughput HIV sequencing. This assay, HIDA (HIV Incidence and Drug Resistance Assay), combines microdroplet technologies and long-read single-molecule sequencing for precise incidence and drug resistance surveillance. HIDA can promote global HIV real-time surveillance, which is in high-demand for the advancement of the 95-95-95 “treatment for all” target. HIDA screens all 93 WHO surveillance drug resistance mutations and detects cross-class linked drug resistance mutations in a single virus (funded by NIH NIAID).
We invented microdrop HIV sequencing for accurate and high-throughput HIV sequencing. This assay, HIDA (HIV Incidence and Drug Resistance Assay), combines microdroplet technologies and long-read single-molecule sequencing for precise incidence and drug resistance surveillance. HIDA can promote global HIV real-time surveillance, which is in high-demand for the advancement of the 95-95-95 “treatment for all” target. HIDA screens all 93 WHO surveillance drug resistance mutations and detects cross-class linked drug resistance mutations in a single virus (funded by NIH NIAID).
